A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• ErbB3 and ErbB4 receptor activation by ligands contributes to various human cancers, including ovarian cancer and melanoma.
• Targeting ErbB signaling pathways is a key strategy in cancer therapy.

Purpose of the Study:

• To develop and characterize a novel ErbB4 fusion protein with enhanced ligand-binding properties.
• To evaluate the therapeutic potential of this fusion protein in preclinical cancer models.

Main Methods:

• Construction and purification of an ErbB4 ectodomain fused to human IgG Fc (sErbB4.497.Fc).
• Assessment of ligand-binding affinity using techniques like K(D) measurements.
• Evaluation of signaling pathway inhibition (e.g., IKB/MAP/JNK/AKT) and cell proliferation assays (MCF7 cells).
• In vivo efficacy testing in a mouse tumor xenograft model (MDA-MB-231 breast cancer cells).

Main Results:

• The sErbB4.497.Fc fusion protein exhibited high-affinity binding to betacellulin and heregulin-β1 (HRG-β1), with a K(D) of 130 pM.
• sErbB4.497.Fc effectively inhibited ligand-stimulated phosphorylation of epidermal growth factor receptor (EGFR) and ErbB2.
• The fusion protein blocked HRG-β1-induced activation of key signaling pathways and inhibited proliferation in MCF7 cells.
• In vivo studies showed modest inhibition of MDA-MB-231 breast cancer tumor growth when sErbB4.497.Fc was used as a monotherapy.

Conclusions:

• The sErbB4.497.Fc fusion protein is a potent inhibitor of ErbB ligand-mediated signaling.
• This novel therapeutic agent demonstrates efficacy in preclinical cancer models.
• sErbB4.497.Fc holds promise as an adjuvant therapy in combination with existing cancer treatments.